What the FDA labels say about taking them together
Bictegravir/lenacapavir and dofetilide
Bictegravir/lenacapavir's FDA label of August 27, 2026 names dofetilide in its contraindications section; the dofetilide label PlainMeds reads does not name bictegravir/lenacapavir. The bictegravir/lenacapavir label: “Coadministration of BIC with drugs that are substrates of OCT2 and MATE1 (e.g., dofetilide) may increase their plasma concentrations (see Table 4 ).”
Check it at the source: the bictegravir/lenacapavir FDA label on DailyMed (effective August 27, 2026, Gilead Sciences, Inc.); the dofetilide FDA label on DailyMed (effective April 21, 2026, Pfizer Laboratories Div Pfizer Inc).
What does the bictegravir/lenacapavir label say about dofetilide?
Bictegravir/lenacapavir label, contraindicationsCONTRAINDICATIONS Concomitant administration of BIXLENVO is contraindicated with: dofetilide due to the potential for increased dofetilide plasma concentrations and associated serious and/or life-threatening events. strong CYP3A inducers due to decreased plasma concentrations of BIC and LEN, which may result in the loss of therapeutic effect and development of resistance to BIXLENVO.
Bictegravir/lenacapavir label, drug interactionsCoadministration of BIC with drugs that are substrates of OCT2 and MATE1 (e.g., dofetilide) may increase their plasma concentrations (see Table 4 ).
Source: FDA drug label (BIXLENVO), Gilead Sciences, Inc., effective August 27, 2026 (SPL set 072a3c7e-33fb-4a87-ba21-3d8dad3f5c48), via openFDA; the full label on DailyMed
What does the dofetilide label say about bictegravir/lenacapavir?
Dofetilide's label (effective April 21, 2026) does not name bictegravir/lenacapavir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Tikosyn), Pfizer Laboratories Div Pfizer Inc, effective April 21, 2026 (SPL set 02438044-d6a3-49e9-a1ac-3aad21ef2c8c), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Bictegravir/lenacapavir | Dofetilide | |
|---|---|---|
| Labeled for | HIV | Atrial fibrillation |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | n/a | $0.203 per capsule 125 mcg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once